Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;24(4):681-692.
doi: 10.1007/s12094-022-02806-x. Epub 2022 Mar 23.

SEOM-GECOD clinical guideline for unknown primary cancer (2021)

Ferrán Losa #  1 , Isaura Fernández #  2 , Olatz Etxaniz #  3 , Alejandra Giménez #  4 , Paula Gomila #  5 , Lara Iglesias #  6 , Federico Longo #  7 , Esteban Nogales #  8 , Antonio Sánchez #  9 , Gemma Soler #  10
Affiliations

SEOM-GECOD clinical guideline for unknown primary cancer (2021)

Ferrán Losa et al. Clin Transl Oncol. 2022 Apr.

Abstract

Cancer of unknown primary site (CUP) is defined as a heterogeneous group of tumors that appear as metastases, and of which standard diagnostic work-up fails to identify the origin. It is considered a separate entity with a specific biology, and nowadays molecular characteristics and the determination of actionable mutations may be important in a significant group of patients. In this guide, we summarize the diagnostic, therapeutic, and possible new developments in molecular medicine that may help us in the management of this unique disease entity.

Keywords: Cancer; Diagnosis; Treatment; Unknown primary site.

PubMed Disclaimer

Conflict of interest statement

Ferran Losa: Advisory or Consultancy: Roche, Amgen; Speaker Bureau: Roche, Amgen,Merck, Sanofi, Servier and Travel/Accommodation or Expenses: Roche, Amgen,Merck, Sanofi. Isaura Fernandez. Consultant or Advisory: Roche, Astra Zeneca; Speaker Bureau: Pfizer, AstraZeneca, Roche,MSD, Clovis,Glaxo. Olatz Etxaniz. Consultant or Advisory: Pfizer, Merck,Ipsen,Roche; Speaker Bureau: Pfizer,Ipsen,BMS; Expenses: Clovis, Pfizer,Janssen,BMS. Alejandra Giménez. Consultant or Advisory: Ipsen; Speaker Bureau: Merck, Ipsen, Sanofi; Expenses: Merck, Amgem, Roche. Paula Gomila. No disclosures. Lara Iglesias. Consultant or Advisory: Merck, MSD, BMS, Lilly, Roche, Bayer, Sanofi. Speaker Bureau: Merck, MSD, BMS, Roche, Bayer, Sanofi, Eisai, Kyowa-kirin. Federico Longo. Advisory/Consultant: Roche, Ferre. Esteban Nogales. Consultant or Advisory: Roche, Daiichi Sankyo; Speaking: Pfizer, AstraZeneca, Roche, Kyowa Kirin. Antonio Sánchez: No disclosures. Gemma Soler. Advisory or Consultancy: Amgem,Roche,Kiowa; Speaker Bureau: Amgem,Merck,Roche, Sanofi, Servier and Travel/Accommodation or Expenses: Amgem, Merck,Roche, Sanofi.

Figures

Fig. 1
Fig. 1
CK 7/CK 20 profile and additional markers. ( Adapted from J Gastrointestin Liver Dis, 2017 (26).1:69–79
See this image and copyright information in PMC

Similar articles

  • SEOM clinical guideline on unknown primary cancer (2017).
    Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ. Losa F, et al. Clin Transl Oncol. 2018 Jan;20(1):89-96. doi: 10.1007/s12094-017-1807-y. Epub 2017 Dec 11. Clin Transl Oncol. 2018. PMID: 29230692 Free PMC article.
  • Clinical guideline SEOM: cancer of unknown primary site.
    Collado Martín R, García Palomo A, de la Cruz Merino L, Borrega García P, Barón Duarte FJ; Spanish Society for Medical Oncology. Collado Martín R, et al. Clin Transl Oncol. 2014 Dec;16(12):1091-7. doi: 10.1007/s12094-014-1244-0. Epub 2014 Nov 13. Clin Transl Oncol. 2014. PMID: 25392080 Free PMC article.
  • Cancer from an unknown primary site.
    Dowell JE. Dowell JE. Am J Med Sci. 2003 Jul;326(1):35-46. doi: 10.1097/00000441-200307000-00006. Am J Med Sci. 2003. PMID: 12861124 Review.
  • Occult primary, version 3.2014.
    Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA; National Comprehensive Cancer Network. Ettinger DS, et al. J Natl Compr Canc Netw. 2014 Jul;12(7):969-74. doi: 10.6004/jnccn.2014.0093. J Natl Compr Canc Netw. 2014. PMID: 24994917
  • From Biology to Diagnosis and Treatment: The Ariadne's Thread in Cancer of Unknown Primary.
    Mathew BG, Aliyuda F, Taiwo D, Adekeye K, Agada G, Sanchez E, Ghose A, Rassy E, Boussios S. Mathew BG, et al. Int J Mol Sci. 2023 Mar 15;24(6):5588. doi: 10.3390/ijms24065588. Int J Mol Sci. 2023. PMID: 36982662 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dykewicz CA. Centers for Disease Control and Prevention (U.S.), infectious diseases society of America, American society of blood and marrow transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33(2):139–144. - PubMed
    1. Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 2019;61:139–141. - PubMed
    1. Conway A-M, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’. Br J Cancer. 2019;120(2):141–153. - PMC - PubMed
    1. Rassy E, Assi T, Pavlidis N. Exploring the biological hallmarks of cancer of unknown primary: where do we stand today? Br J Cancer. 2020;122(8):1124–1132. - PMC - PubMed
    1. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol. 2009;11(6):340–348. - PubMed

MeSH terms